

David Nanchen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3589401/publications.pdf>

Version: 2024-02-01

73
papers

3,133
citations

257357

24
h-index

161767

54
g-index

74
all docs

74
docs citations

74
times ranked

5554
citing authors

#	ARTICLE	IF	CITATIONS
1	Subclinical Thyroid Dysfunction and the Risk of Heart Failure Events. <i>Circulation</i> , 2012, 126, 1040-1049.	1.6	410
2	Meta-analysis: Subclinical Thyroid Dysfunction and the Risk for Coronary Heart Disease and Mortality. <i>Annals of Internal Medicine</i> , 2008, 148, 832.	2.0	405
3	Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors. <i>European Heart Journal</i> , 2017, 38, ehw582.	1.0	317
4	Comparison of Application of the ACC/AHA Guidelines, Adult Treatment Panel III Guidelines, and European Society of Cardiology Guidelines for Cardiovascular Disease Prevention in a European Cohort. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1416.	3.8	301
5	Subclinical Thyroid Dysfunction and the Risk of Heart Failure in Older Persons at High Cardiovascular Risk. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 852-861.	1.8	178
6	Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes. <i>European Heart Journal</i> , 2015, 36, 2438-2445.	1.0	129
7	Prognostic value of PCSK9 levels in patients with acute coronary syndromes. <i>European Heart Journal</i> , 2016, 37, 546-553.	1.0	120
8	Prognosis of Patients With Familial Hypercholesterolemia After Acute Coronary Syndromes. <i>Circulation</i> , 2016, 134, 698-709.	1.6	99
9	Trimethyllysine, a trimethylamine N-oxide precursor, provides near- and long-term prognostic value in patients presenting with acute coronary syndromes. <i>European Heart Journal</i> , 2019, 40, 2700-2709.	1.0	79
10	Profiling and validation of circulating microRNAs for cardiovascular events in patients presenting with ST-segment elevation myocardial infarction. <i>European Heart Journal</i> , 2017, 38, ehw563.	1.0	77
11	Improved risk stratification of patients with acute coronary syndromes using a combination of hsTnT, NT-proBNP and hsCRP with the GRACE score. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018, 7, 129-138.	0.4	70
12	Resting Heart Rate and the Risk of Heart Failure in Healthy Adults. <i>Circulation: Heart Failure</i> , 2013, 6, 403-410.	1.6	69
13	Resting heart rate and incident heart failure and cardiovascular mortality in older adults: role of inflammation and endothelial dysfunction: the PROSPER study. <i>European Journal of Heart Failure</i> , 2013, 15, 581-588.	2.9	57
14	Cysteine-rich angiogenic inducer 61 (Cyr61): a novel soluble biomarker of acute myocardial injury improves risk stratification after acute coronary syndromes. <i>European Heart Journal</i> , 2017, 38, 3493-3502.	1.0	46
15	Impact of Carotid Plaque Screening on Smoking Cessation and Other Cardiovascular Risk Factors. <i>Archives of Internal Medicine</i> , 2012, 172, 344.	4.3	39
16	Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland. <i>Heart</i> , 2015, 101, 854-863.	1.2	38
17	Alcohol drinking, the metabolic syndrome and diabetes in a population with high mean alcohol consumption. <i>Diabetic Medicine</i> , 2010, 27, 1241-1249.	1.2	37
18	Reasons for discontinuation of recommended therapies according to the patients after acute coronary syndromes. <i>European Journal of Internal Medicine</i> , 2015, 26, 56-62.	1.0	37

#	ARTICLE	IF	CITATIONS
19	Resting heart rate: what is normal?. <i>Heart</i> , 2018, 104, 1048-1049.	1.2	36
20	Predictive value of the age, creatinine, and ejection fraction (ACEF) score in patients with acute coronary syndromes. <i>International Journal of Cardiology</i> , 2018, 270, 7-13.	0.8	33
21	Eligibility for PCSK9 inhibitors based on the 2019 ESC/EAS and 2018 ACC/AHA guidelines. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 59-65.	0.8	30
22	Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	29
23	Quality of Care after Acute Coronary Syndromes in a Prospective Cohort with Reasons for Non-Prescription of Recommended Medications. <i>PLoS ONE</i> , 2014, 9, e93147.	1.1	28
24	Expected impact of applying new 2013 AHA/ACC cholesterol guidelines criteria on the recommended lipid target achievement after acute coronary syndromes. <i>Atherosclerosis</i> , 2015, 239, 118-124.	0.4	26
25	Prognostic value of elevated lipoprotein(a) in patients with acute coronary syndromes. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13117.	1.7	24
26	Childhood adversity: A gateway to multimorbidity in older age?. <i>Archives of Gerontology and Geriatrics</i> , 2019, 80, 31-37.	1.4	24
27	Inflammation during acute coronary syndromes – Risk of cardiovascular events and bleeding. <i>International Journal of Cardiology</i> , 2019, 287, 13-18.	0.8	22
28	Prognosis of cardiovascular and non-cardiovascular multimorbidity after acute coronary syndrome. <i>PLoS ONE</i> , 2018, 13, e0195174.	1.1	21
29	Diabetes and baseline glucose are associated with inflammation, left ventricular function and short- and long-term outcome in acute coronary syndromes: role of the novel biomarker Cyr 61. <i>Cardiovascular Diabetology</i> , 2019, 18, 142.	2.7	21
30	Comparison of Swiss and European risk algorithms for cardiovascular prevention in Switzerland. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 204-210.	0.8	21
31	Low statin use in adults hospitalized with acute coronary syndrome. <i>Preventive Medicine</i> , 2015, 77, 131-136.	1.6	18
32	Uptake and efficacy of a systematic intensive smoking cessation intervention using motivational interviewing for smokers hospitalised for an acute coronary syndrome: a multicentre before-after study with parallel group comparisons. <i>BMJ Open</i> , 2016, 6, e011520.	0.8	18
33	Identifying familial hypercholesterolemia in acute coronary syndrome. <i>Current Opinion in Lipidology</i> , 2016, 27, 375-381.	1.2	18
34	Evaluation of contemporary treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe – Methodology and rationale for the multinational observational SANTORINI study. <i>Atherosclerosis Plus</i> , 2021, 43, 24-30.	0.3	17
35	Prognostic value of pulse pressure after an acute coronary syndrome. <i>Atherosclerosis</i> , 2018, 277, 219-226.	0.4	15
36	Health utility indexes in patients with acute coronary syndromes. <i>Open Heart</i> , 2016, 3, e000419.	0.9	14

#	ARTICLE	IF	CITATIONS
37	Novel Blood Biomarkers for a Diagnostic Workup of Acute Aortic Dissection. <i>Diagnostics</i> , 2021, 11, 615.	1.3	14
38	Non-Linear Relationship between Anti-Apolipoprotein A-1 IgGs and Cardiovascular Outcomes in Patients with Acute Coronary Syndromes. <i>Journal of Clinical Medicine</i> , 2019, 8, 1002.	1.0	11
39	Trends in Physical and Cognitive Performance Among Community-Dwelling Older Adults in Switzerland. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2020, 75, 2347-2353.	1.7	11
40	Cardiovascular Risk Estimation and Eligibility for Statins in Primary Prevention Comparing Different Strategies. <i>American Journal of Cardiology</i> , 2009, 103, 1089-1095.	0.7	10
41	Associations Between Cardiovascular Risk Factors, Inflammation, and Progression of Carotid Atherosclerosis Among Smokers. <i>Nicotine and Tobacco Research</i> , 2016, 18, 1533-1538.	1.4	10
42	Improving 1-year mortality prediction in ACS patients using machine learning. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 855-865.	0.4	9
43	Do baby boomers feel healthier than earlier cohorts after retirement age? The Lausanne cohort Lc65+ study. <i>BMJ Open</i> , 2019, 9, e025175.	0.8	8
44	Prognosis of Patients with Chronic and Hospital-Acquired Anaemia After Acute Coronary Syndromes. <i>Journal of Cardiovascular Translational Research</i> , 2020, 13, 618-628.	1.1	8
45	Effectiveness, Adherence, and Safety of Evolocumab in a Swiss Multicenter Prospective Observational Study. <i>Advances in Therapy</i> , 2022, 39, 504-517.	1.3	8
46	Statins for Cardiovascular Prevention According to Different Strategies. <i>American Journal of Cardiovascular Drugs</i> , 2011, 11, 33-44.	1.0	7
47	Thrombus aspiration in acute coronary syndromes: prevalence, procedural success, change in serial troponin T levels and clinical outcomes in a contemporary Swiss cohort. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018, 7, 522-531.	0.4	7
48	Prognostic values of fasting hyperglycaemia in non-diabetic patients with acute coronary syndrome: A prospective cohort study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 589-598.	0.4	7
49	Prognostic value of total testosterone levels in patients with acute coronary syndromes. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 235-242.	0.8	7
50	Residual inflammatory risk at 12 months after acute coronary syndromes is frequent and associated with combined adverse events. <i>Atherosclerosis</i> , 2021, 320, 31-37.	0.4	7
51	Public health impact of statin prescribing strategies based on JUPITER. <i>Preventive Medicine</i> , 2011, 52, 159-163.	1.6	6
52	Clinical impact of a structured secondary cardiovascular prevention program following acute coronary syndromes: A prospective multicenter healthcare intervention. <i>PLoS ONE</i> , 2019, 14, e0211464.	1.1	6
53	Optimal Timing of Invasive Coronary Angiography following NSTEMI. <i>Journal of Interventional Cardiology</i> , 2020, 2020, 1-9.	0.5	6
54	CCN family member 1 (CCN1) is an early marker of infarct size and left ventricular dysfunction in STEMI patients. <i>Atherosclerosis</i> , 2021, 335, 77-83.	0.4	6

#	ARTICLE	IF	CITATIONS
55	Mortality Associated with Diabetes and Cardiovascular Disease in Older Women. <i>PLoS ONE</i> , 2012, 7, e48818.	1.1	6
56	Cohort Profile: The Lausanne cohort 65+ (Lc65+). <i>International Journal of Epidemiology</i> , 2022, 51, e156-e166.	0.9	6
57	Intensified lipid lowering using ezetimibe after publication of the IMPROVE-IT trial: A contemporary analysis from the SPUM-ACS cohort. <i>International Journal of Cardiology</i> , 2020, 303, 8-13.	0.8	5
58	Prognostic role of plasma galectin-3 levels in acute coronary syndrome. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 869-878.	0.4	5
59	Impact of malignancy on clinical outcomes in patients with acute coronary syndromes. <i>International Journal of Cardiology</i> , 2021, 328, 8-13.	0.8	5
60	Prognostic value of inflammatory biomarkers and GRACE score for cardiac death and acute kidney injury after acute coronary syndromes. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 445-452.	0.4	5
61	Identification and molecular characterisation of Lausanne Institutional Biobank participants with familial hypercholesterolaemia – a proof-of-concept study. <i>Swiss Medical Weekly</i> , 2016, 146, w14326.	0.8	5
62	Is atherosclerosis imaging the most sensitive way to assess patients' risk and the best way to conduct future drug trials? A pros-and-cons debate. <i>Atherosclerosis</i> , 2017, 266, 229-233.	0.4	4
63	Cysteine-Rich Angiogenic Inducer 61 Improves Prognostic Accuracy of GRACE (Global Registry of Acute) Tj ETQq1 1 0.784314 rgBT <i>Heart Association</i> , 2021, 10, e020488.	1.6	4
64	Combining bone resorption markers and heel quantitative ultrasound to discriminate between fracture cases and controls. <i>Osteoporosis International</i> , 2009, 20, 1695-1703.	1.3	3
65	Gender and age differences in outcomes of patients with acute coronary syndromes referred for coronary angiography. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 16-24.	0.7	3
66	Older People's Health-Related Behaviors: Evidence from Three Cohorts of the Lc65+ Study. <i>Behavioral Medicine</i> , 2020, 47, 1-5.	1.0	2
67	Hospital revascularisation capability and quality of care after an acute coronary syndrome in Switzerland. <i>Swiss Medical Weekly</i> , 2016, 146, w14275.	0.8	2
68	Smoking Cessation in People With and Without Diabetes After Acute Coronary Syndrome. <i>Nicotine and Tobacco Research</i> , 2023, 25, 58-65.	1.4	2
69	Control of cardiovascular risk factors and health behaviors in patients post acute coronary syndromes eligible for protein convertase subtilisin/kexin-9 inhibitors. <i>International Journal of Cardiology</i> , 2020, 299, 289-295.	0.8	1
70	Association between income and control of cardiovascular risk factors after acute coronary syndromes: an observational study. <i>Swiss Medical Weekly</i> , 2019, 149, w20049.	0.8	1
71	Carotid plaque screening as a motivational tool for healthy behavior. <i>American Heart Journal</i> , 2008, 155, e37.	1.2	0
72	Association between self-reported motivation to quit smoking with effectiveness of smoking cessation intervention among patients hospitalized for acute coronary syndromes in Switzerland. <i>Preventive Medicine Reports</i> , 2021, 24, 101583.	0.8	0

#	ARTICLE	IF	CITATIONS
73	Abstract 15491: Effects of Intensive Smoking Cessation Counseling After Acute Coronary Syndrome on 5-year Incidence of Major Adverse Cardiovascular Events and Smoking Abstinence. <i>Circulation</i> , 2020, 142, .	1.6	0